A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia.

Twenty-one patients with postherpetic neuralgia of two- to 84-months duration participated in a double-blind, placebo-controlled study of oral acyclovir. Pain perception was assessed with the Melzack Pain Questionnaire at baseline and at two-to six-week intervals during the ensuing six months. Clinically significant pain reduction occurred in eight patients: four received acyclovir, and four received a placebo. Several treatment strategies have been advocated for relief of postherpetic neuralgia. Results of the present study demonstrate the need for a double-blind, placebo-controlled paradigm to substantiate the efficacy of new clinical approaches. The same caveat applies to the more common syndromes encountered in psychiatric practice.
AuthorsO S Surman, T Flynn, R T Schooley, L Baer, S Parker, M S Hirsch, L G Davis
JournalPsychosomatics (Psychosomatics) Vol. 31 Issue 3 Pg. 287-92 ( 1990) ISSN: 0033-3182 [Print] UNITED STATES
PMID2201992 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Acyclovir
  • Acyclovir (administration & dosage)
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Herpes Zoster (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Neuralgia (drug therapy)
  • Pain Measurement

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: